Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Caprelsa vandetanib regulatory update

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said thyroid cancer drug Caprelsa vandetanib from AstraZeneca provides "no additional benefit" over best

Read the full 230 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE